Is herpes zoster a marker for occult or subsequent malignancy?

British Journal of General Practice

Volumn 55, Issue 511, 2005, Pages 102-107

  Buntinx, Frank ^a,b   Wachana, Richard ^c   Bartholomeeusen, Stefaan ^a   Sweldens, Kathleen ^d   Geys, Helena ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c HASSELT UNIVERSITY   (Belgium)

^d Medisch Centrum voor Huisartsen   (Belgium)

Author keywords

Cohort studies; Herpes zoster; Neoplasm; Survival analysis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENERAL PRACTICE; GROUPS BY AGE; HERPES ZOSTER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; POPULATION DISTRIBUTION; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HERPES ZOSTER; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 13844256643     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Smith JB, Fenske NA. Herpes zoster and internal malignancy. South Med J 1995; 88: 1089-1092.
2. Fueyo MA, Lookingbill DP. Herpes zoster and occult malignancy. J Am Acad Dermatol 1984; 11: 480-482.
3. Ragozzino MW, Melton LJ III, Kurland LT, et al. Risk of cancer after herpes zoster: a population-based study. N Engl J Med 1982; 307: 393-397.
4. Bartholomeeusen S, Buntinx F, De Cock L, Heyrman J. The incidence of diseases in general practice. Leuven: Acco, 2001.
5. Gebel RS, Okkes IM, red. ICPC-2-NL. The International Classification of Primary Care. Tweede druk, Nederlandse versie. Utrecht, Amsterdam: Nederlands Huisartsen Genootschap, Academisch Medisch Centrum/Universiteit van Amsterdam, 2000.
6. Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996; 2: 12-16.
7. Buntinx F, Claes E, Dhollander D, et al. Incidence of cancer in the Belgian province of Limburg 1996-1998. Hasselt: Limburgse Kanker Stichting, 2000.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
9. Cox DR. Regression models and life tables (with discussion). J R Statist Soc 1972; B74: 187-220.
10. Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
11. Allison PD. Survival analysis using the SAS® System. Cary, NC: SAS Institute Inc, 1995.
12. Wyburn-Mason R. Malignant change arising in tissue affected by herpes. BMJ 1955; 2: 1106-1109.
13. Brown GR. Herpes zoster: correlation of age, sex, distribution, neuralgia, and associated disorders. South Med J 1976; 69: 576-578.
14. Serraino D, Franceschi S, Talamini R, et al. Socio-economic indicators, infectious diseases and Hodgkin's disease. Int J Cancer 1991; 47: 352-357.
15. Cuzick J, De Stavola B. Multiple myeloma - a case control study. Br J Cancer 1988; 57(5): 516-520.
16. Gramenzi A, Buttino I, D'Avanzo B, et al. Medical history and the risk of multiple myeloma. Br J Cancer 1991; 63(5): 769-772.
17. La Vecchia C, Negri E, Franceschi S. Medical history and the risk of non-Hodgkin lymphomas. Cancer Epidemiol Biomarkers Prev 1992; 1(7): 553-556.
18. Wolff HH, Wendt V, Winzer M. Cutaneous pseudolymphoma at the site of prior herpes zoster eruption. Arch Dermatological Res 1987; 279: S52-S54.
19. Hudson CP, Hanno R, Callen JP. Cutaneous angiosarcoma in a site of healed herpes zoster. Int J Dermatol 1984; 23: 404-407.
20. Konjevic G, Jurisic V, Banicevic B, Spuzic I. The difference in NK-cell activity between patients with non-Hodgkins lymphomas and Hodgkin's disease. Br J Haematol 1999; 104: 144-151.
21. Yang CM, Yang YH, Lin YT, et al. Natural killer cell deficiency associated with Hodgkin's lymphoma. J Formos Med Assoc 2002; 101: 73-75.